AptarGroup, Inc. signed a share purchase agreement to acquire 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel for €50.1 million.

AptarGroup, Inc. (NYSE:ATR) signed a share purchase agreement to acquire 64.6% stake in Voluntis S.A. from Vesalius Biocapital Partners S.à r.l, LBO France, Sham Innovation Santé, Bpifrance Participations SA, Debiopharm Innovation Fund SA and Eric Carreel for €50.1 million on July 22, 2021. AptarGroup will pay €8.7 per share. After and subject to completion of this acquisition, Aptar will launch a mandatory cash tender offer to acquire Voluntis' remaining shares for the same price of €8.7 per share.

The transaction is subject to customary conditions, notably the approval of the French Ministry of Economy under the foreign investment clearance regulations. The completion of the transfer of the block of shares is expected to occur before the end of the third quarter 2021. Matthieu Grollemund, Pierre-Marie Boya, Gautier Valdiguié and Martin Noire, Eric Paroche, Céline Verney, Thomas Claudel, and Marion Guertault of Hogan Lovells advised Voluntis as part of the transaction.

Jeremy Scemama and Fabien Goudot of DLA Piper France LLP acted as legal advisor to Bpifrance Participations SA.